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STAT5 Phosphorylation in Malignant Melanoma Is
Important for Survival and Is Mediated Through SRC
and JAK1 Kinases
Alireza Mirmohammadsadegh1,4, Mohamad Hassan1,4, Walter Bardenheuer1,4, Alessandra Marini1, Annett
Gustrau1, Sandeep Nambiar1, Andrea Tannapfel2, Hans Bojar3, Thomas Ruzicka1 and Ulrich R. Hengge1
Altered signaling pathways are key regulators of cellular functions in tumor cells. Constitutive activation of
signal transducer and activator of transcription (STAT)3 and -5 may be involved in tumor formation and
progression. We have investigated the role of STAT5 in cutaneous melanoma metastases using various RNA and
protein techniques. In melanoma specimens, Stat5b transcripts were upregulated approximately 3.8-fold. In 13
of 21 (62%) human melanoma metastases, STAT5 was phosphorylated in comparison to normal human
melanocytes and benign nevi. The STAT5 target gene Bcl-2 was frequently upregulated. The investigation of the
underlying mechanism revealed specific STAT5 activation by recombinant human epidermal growth factor
(rEGF). rEGF-induced activation of STAT5 occurred in vitro through the non-receptor tyrosine kinases
transforming gene (src) of Rous Sarcoma virus and Janus kinase 1. Inhibition of Stat5b expression by small
interfering RNA strongly reduced the expression of Bcl-2 and led to decreased cell viability and increased
apoptosis in the melanoma cell lines A375 and BLM. Transfection with dominant-negative Stat5b caused
enhanced cell death and G1 arrest in A375 cells. Our study identifies phosphorylated STAT5 in melanoma and
shows regulation through rEGF; STAT5 may thus act as a survival factor for growth of human melanoma and may
represent a potential target for molecular therapy.
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INTRODUCTION
Signal transducers and activators of transcription (STATs)
represent a family of transcription factors that are located
in the cytoplasm and are activated by a variety of different
stimuli such as cytokines, growth hormones, and various
tumor promoters, for example, 12-O-tetradecanoylphorbol-13-
acetate, ocadaic acid, and chrysarobin (Darnell, 1997; Chan
et al., 2004). Upon binding of the ligand to the corresponding
receptor, receptors become phosphorylated by receptor-asso-
ciated tyrosine kinases like Janus kinase (JAK) (Darnell et al.,
1994). Receptors with intrinsic tyrosine kinase activity such as
the EGFR are able to autophosphorylate tyrosine residues and
interact directly with STAT proteins (Coffer and Kruijer, 1995).
Recent studies have demonstrated the activation of STATs by
diverse proto-oncogenic non-receptor tyrosine kinases like v-
SRC (Garcia et al., 1997), LYN (Chin et al., 1998), BCR/ABL
(Carlesso et al., 1996), and LCK (Lund et al., 1999). The
recruitment of STAT molecules with receptor or non-receptor
tyrosine kinases occurs via a conserved SRC (transforming gene
(src) of Rous Sarcoma virus)-homology-2 domain (Rosen et al.,
1995). Upon homo- or heterodimerization phosphorylated
STATs translocate to the nucleus and bind to STAT-specific
DNA-response elements of target genes and induce gene
expression (Darnell, 1997). STAT target genes are involved in
the control of different biological processes such as prolifera-
tion, apoptosis, survival, differentiation, and angiogenesis
(Darnell, 1997; Levy and Darnell, 2002; Chan et al., 2004).
Constitutive activation of STAT3 has been linked to oncogenic
transformation, tumor formation, and progression (Bowman
et al., 2000; Calo et al., 2003; Yamashita et al., 2003; Li et al.,
2004) in esophageal cancer (Leu et al., 2003), gastrointestinal
stroma tumors (Duensing et al., 2004), melanoma (Niu et al.,
2002a), and multiple myeloma (Chatterjee et al., 2004).
While STAT5 plays a key role in the regulation of
hematopoietic differentiation and stem cell function (Darnell,
1997; Kyba et al., 2003; Chan et al., 2004), it has only recently
been discovered to be involved in malignant transformation of
hematological malignancies (Lin et al., 2000), breast (Yamashita
et al., 2003), and prostate cancer (Li et al., 2004) as well as
human non-small-cell carcinoma (Xi et al., 2003).
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Inhibition of STAT3 signaling in tumor cells induced
apoptosis and/or growth arrest in vitro and in vivo (Niu et al.,
2001). For example, dominant-negative STAT3 in human
myeloma cells downregulated the expression of the anti-
apoptotic gene Bcl-2, resulting in sensitization of cells
towards Fas-mediated apoptosis (Catlett-Falcone et al.,
1999; Grandis et al., 2000). STAT3 has also been found
activated in murine melanoma leading to an upregulation of
Bcl-2 and c-MYC (Niu et al., 1999, 2002a).
The potential impact of STAT5 as a point of convergence
in melanoma has remained unexplored. In this study, we
examined STAT5 in human melanoma specimens and
investigated the activation of STAT5 by the EGFR tyrosine
kinase as well as by the non-receptor tyrosine kinases JAK1
and SRC in vitro. To elucidate the functional effects of STAT5
in melanoma, Stat5b expression was inhibited by small
interfering RNA (siRNA) experiments leading to decreased
Bcl-2 and increased apoptosis. When a dominant-negative
human Stat5b construct was expressed in melanoma
cell lines, enhanced cell death and G1-arrest were also
observed.
RESULTS
Activation of STAT5 in human melanoma metastases
To investigate a possible role of STAT5 in melanoma, we
examined the transcription and protein expression levels as
well as the activation of STAT5 in human melanoma
metastases using real-time PCR, Western blot analysis, and
immunohistochemistry (Figures 1 and 2). The expression of
Stat5b mRNA was 3.8-fold upregulated compared to normal
human melanocyte (NHM) (Figure 1a; P¼0.0002). Further-
more, STAT5 protein was constitutively expressed in mela-
noma samples and benign nevi, but very weakly in NHM
(Figure 1c and d), with STAT5 being phosphorylated in 13 of
21 (62%) analyzed melanoma specimens in contrast to NHM
(Figure 1b). In addition, we investigated the tyrosine
phosphorylation of STAT5 in different melanoma cell lines
in cytoplasmatic as well as in nuclear fractions (Figure 1d).
P-STAT5 was present in low amounts in cytoplasmatic extracts
of BLM, M13, and MV3, but was absent in the A375 human
melanoma cell line (Figure 1d). The immunohistochemical
data are summarized together with clinical information in
Table 1. Immunohistochemically, P-STAT5 was also highly
abundant in 13 of 23 (56%) analyzed metastases (Figure 2c
and d), whereas unphosphorylated STAT5 showed constitu-
tive levels (Figure 2a and b). Cutaneous melanoma meta-
stases showed nests of melanoma cells with predominant
cytoplasmatic and little nuclear STAT5 staining detectable
upon higher magnification (Figure 2b). A corresponding
section showed more intense staining with P-STAT5, where
most cells contained cytoplasmatic and pronounced nuclear
staining (Figure 2d). In total, two of four primary melanoma
and 11 of 19 cutaneous metastases showed activated STAT5
in histological sections (Table 1). In consecutive sections of
primary melanoma, some P-STAT5-positive melanoma cells
also stained with an EGFR antibody (Figure 2e and f).
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Figure 1. Expression analysis of STAT5. (a) Real-time PCR analysis shows upregulation of stat5b transcripts in 13 human melanoma specimens. Bar graph shows
expression of stat5b in melanoma lesions relative to NHM. The expression of stat5b was on average 3.8 times higher compared to NHM (n¼ 3; t-test;
P¼ 0.0002). Variation coefficients for CT values for triplicate reactions were less than 1% for all gene products (data not shown). (b) Expression of STAT5
and P-STAT5 in melanoma specimens by Western blot analysis. P-STAT5 was present in 13 of 21 (62%) metastatic melanomas, whereas it was absent in
NHM; depicted are seven representative samples. STAT5 protein was present in all melanoma samples while it was low in NHM. Equal protein loading
was confirmed by staining for b-actin. (c) Electrophoretic mobility shift assay to demonstrate STAT-5 in two of three tested clinical samples (d) P-STAT5
Western blot analysis from cytoplasmatic and nuclear fractions of different melanoma cell lines (BLM, MV3, M13, and A375). P-STAT5 was absent in
the nuclear fraction of all four analyzed cell lines. Basic levels of activated STAT5 were present in cytoplasmatic extracts of M13 cells and were very low
in BLM, and MV3 cells. In the A375 cell line, P-STAT5 was absent in both cytoplasmatic and nuclear extracts.
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Analysis of STAT5 target genes
As activated STAT5 induces antiapoptotic signals, we
analyzed the regulation of several STAT5 target genes
involved in apoptosis. The antiapoptotic protein Bcl-2 was
consistently detectable in all tumor specimens, melanoma
cell lines as well as in NHM (Figure 3).
Correlation of STAT5 activation with EGFR expression
STAT proteins are activated by different receptors in a cell-
and ligand-specific manner. As we have previously shown
the responsiveness of NHM and A375 cells to epidermal
growth factor (EGF) leading to phosphorylation of STAT5
(Mirmohammadsadegh et al., 2005) (Figure 4a), we investi-
gated the levels of EGF receptors on these cell lines. By
Western blot analysis, EGFR levels were high on NHM,
A375, and HaCaT cells, whereas they were low in BLM,
MV3, and absent in M13 (Figure 4b), respectively. The
expression of EGFR correlated with the activation of STAT5
induced by EGF in A375 cells (Figure 4c). Phosphorylation of
STAT5 occurred after 5 minutes and lasted for up to 1 hour. As
we have previously shown high levels of EGFR in melanoma
metastases and primary melanoma in comparison with
benign nevi (Mirmohammadsadegh et al., 2005). A375 cells
seemed to be the best model of clinical melanoma and were
consequently chosen for further experiments.
Activation of STAT5 is mediated by SRC and JAK1 tyrosine
kinases
To characterize the recombinant human epidermal growth
factor (rEGF)-induced STAT5 activation, we investigated the
role of SRC and JAK tyrosine kinases. As shown in Figure 4c,
JAK1 and SRC were activated by rEGF after 1 minute, whereas
JAK2 was weakly phosphorylated after 30 minutes. Chemical
inhibition of JAKs by AG490 and SRC by peroxisome
proliferator (PP) 1 and PP 2, respectively, blocked EGF-
stimulated activation of STAT5 (Figure 4d), suggesting that
both JAKs and SRC are required for maximal activation of
STAT5 in human melanoma. In addition, immunoprecipita-
tion with an EGFR antibody in A375 cells treated with rEGF
revealed an interaction of the EGFR with P-SRC (Figure 4e).
Furthermore, under the same conditions, immunoprecipita-
tion with P-SRC showed P-STAT5 immunostaining, suggest-
ing a direct interaction between both molecules (Figure 4f).
Together, these data suggested that upon rEGF stimulation,
STAT5 is directly phosphorylated by SRC.
Influence of rEGF on STAT5 DNA-binding activity
Activation of STATs induces homo- or heterodimerization
and translocation to the nucleus, resulting in transcription of
STAT target genes. In order to analyze this event, we
stimulated A375 cells with rEGF and utilized cytoplasmatic
and nuclear extracts for the detection of P-STAT5 (Figure 5a).
Fifteen minutes after rEGF stimulation, P-STAT5 was present
in the cytoplasm and in the nucleus (Figure 5a), whereas
under non-stimulated conditions nuclear P-STAT5 was not
detected (Figure 1d). To examine the role of STAT5 in the
regulation of transcription induced by rEGF, we analyzed
STAT5 DNA-binding activity by supershift experiments in the
presence of P-STAT3, P-STAT5, extracellular signal-regulated
kinase (ERK)1/2, and P-ERK1/2 antibodies (Figure 5b). The
nuclear extracts were prepared and assayed for STAT5 DNA-
binding activity with a g-32P-ATP labeled oligonucleotide
probe containing STAT5 consensus binding sites. The rEGF-
induced DNA-binding complex could be supershifted
with anti-P-STAT5 (and weakly with anti-P-STAT3), but
not with control antibodies against ERK1/2 and P-ERK1/2,
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Figure 2. Immunohistochemistry of STAT5, P-STAT5 and EGF-R. Immunohistochemically, a representative sample of a (a) metastatic melanoma showed, upon
higher magnification, (b) predominant cytoplasmatic STAT5 staining. (c) A corresponding section showed intense staining with P-STAT5 . Upon higher
magnification, most cells contained cytoplasmatic and pronounced nuclear staining (* in d). Of note, some tumor cells were negative for P-STAT5. (e) Some
P-STAT5-positive melanoma cells also stained with an EGFR antibody in consecutive sections of (f) primary melanoma. The appropriate isotype controls
showed no staining (data not shown). Bar¼ 50 mm in (a) and (c) and 25mm in (b) and (d)–(f), respectively.
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demonstrating the presence of STAT5 protein in these
complexes (Figure 5b).
Inhibition of STAT5B reduces Bcl-2 levels and enhances
apoptosis
Treatment of A375 and BLM cells with siRNA-Stat5 resulted
in efficient and specific inhibition of Stat5b transcripts
(Figure 6). The siRNA-Stat5 reduced significantly the Bcl-2
and cyclin D2 transcription in A375 cells, two Stat5 target
genes with antiapoptotic and proliferative function. These
data correlated with the overexpression of Bcl-2 in melanoma
metastases (Figure 3). The depletion of Stat5b by specific
siRNA reduced cell viability after 48 hours as evidenced by a
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide assay (Figure 7a and b). We observed a 21.6%
reduction in cell viability by BLM cells and 13.7% by A375
cells compared to mock siRNA. This suggested that STAT5B
is involved in transcriptional regulation of genes such as Bcl-
2 that are involved in cell viability. Furthermore, siRNA-Stat5
induced apoptosis in BLM (1.5-fold) and A375 (2.58-fold;
Po0.05) cells as revealed by 5,50,6,60-tetrachloro-1,10,3,30-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) FACS
staining (Figure 7c and d), which measures the mitochondrial
membrane potential, the loss of which is a hallmark of
apoptosis. To confirm the JC-1 results suggesting apoptosis,
annexinV staining was performed on unstained, non-target
and siRNA-Stat5b-treated A375 and BLM cells (Figure 8a and
b). As can be seen, upon treatment with siRNA-Stat5 more
than 35% of A375 and 65% of BLM cells became annexinV
Table 1. Clinical characteristics
Sex Age (years) Tumor type Primary tumor site Clark’s level P-STAT5
1 M 68 NM Leg IV +
2 F 83 SSM Head IV 
4 F 72 SSM Foot V +
5 F 75 SSM Arm IV 
3 F 77 Cutaneous metastasis Leg +
6 M 80 Cutaneous metastasis Arm 
7 M 69 Cutaneous metastasis Leg +
8 M 48 Cutaneous metastasis Leg 
9 M 62 Cutaneous metastasis Head 
10 F 65 Cutaneous metastasis Leg +
11 M 52 Cutaneous metastasis Trunk +
12 F 71 Cutaneous metastasis Trunk +
13 M 68 Cutaneous metastasis Leg 
14 M 67 Cutaneous metastasis Head +
15 M 71 Cutaneous metastasis Head 
16 M 62 Cutaneous metastasis Helix 
17 F 89 Cutaneous metastasis Leg +
18 F 71 Cutaneous metastasis Trunk +
19 M 51 Cutaneous metastasis Arm 
20 M 67 Cutaneous metastasis Leg +
21 M 85 Cutaneous metastasis Foot +
22 M 68 Cutaneous metastasis Leg 
23 F 75 Cutaneous metastasis Arm +
F: female; M: male; NM: primary nodular melanoma; SSM: primary superficial spreading melanoma.
Important clinical and demographic information is detailed along with the results of P-STAT5 immunohistochemistry staining. For primary tumors, the
Breslow index (vertical diameter in mm) and the Clark level (depth of invasion into the skin) are also depicted. Note that 13 of 23 (56%) of melanoma
specimens were positive for P-STAT5 by immunohistochemistry. The appropriate isotype controls showed no staining (data not shown).
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Figure 3. Expression of STAT5 target genes with relevance for apoptosis. The
antiapoptotic protein BCL-2 was consistently detectable in all clinical
specimens, melanoma cell lines, and in NHM, including A375.
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positive (Figure 8a and b). These results are consistent with
the finding that depletion of Stat5b reduced the levels of the
antiapoptotic gene Bcl-2 (Figure 6). Despite the multiple
pleiotrophic effects of siRNA, our data support the impor-
tance of STAT5 for survival of melanoma cells.
Expression of dominant-negative STAT5B
To confirm the functional effects of siRNA directed against
Stat5b, we performed transfection assays expressing
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Figure 4. Effect of rEGF on melanoma cell lines. (a) A375 cells were treated with increasing doses of rEGF (0.1–100 ng/ml EGF) for 15 minutes leading to
STAT5 phosphorylation. (b) NHM and various melanoma cell lines (A375, BLM, MV3, and M13) were analyzed for EGFR by Western blot analysis.
NHM and A375 cells showed the highest EGFR levels, whereas BLM cells had significantly lower amounts of EGFR. HaCaT cells (immortalized epithelial
cell line) were used as positive control. (c) Time course of treatment with 100 ng/ml rEGF showing activation of STAT5 after 5 minutes with the maximal
activity occurring between 15 and 30 minutes. The activation was absent at 6 hours. The STAT-interacting proteins JAK1 and SRC were phosphorylated
after 1 minute. JAK1 activation continued until 1 hour, whereas SRC phosphorylation was absent after 30 minutes. The JAK2 signal was very weak.
(d) Preincubation of A375 cells with the SRC inhibitors PP1 and PP2 (each 10 mM, 15 minutes before stimulation with 100 ng/ml rEGF) abolished STAT5
phosphorylation. AG490, a JAK inhibitor (50mM), and AG1478, an EGFR inhibitor (25 mM), were added 3 hours prior to EGF stimulation, respectively.
Activation of STAT5 was inhibited by SRC as well as by JAK and EGFR inhibitors, respectively. (e) Immunoprecipitation (IP) with the EGFR antibody and
Western blot (WB) analysis with a P-SRC antibody before and after rEGF treatment showing a direct interaction. (f) IP with a P-SRC antibody followed by
immunostaining with a P-STAT5 antibody. Upon rEGF treatment, SRC directly interacts with STAT5.
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Figure 5. Activation of STAT5 by rEGF and supershift analysis. A375
melanoma cells were stimulated with 100 ng/ml rEGF for 15 minutes when
nuclear extraction was performed. (a) Western blot analysis of nuclear and
cytoplasmatic extracts before and after rEGF treatment confirming the
phosphorylation of STAT5. Within 15 minutes, P-STAT5 translocated from the
cytoplasm to the nucleus. (b) Supershift analysis was performed using nuclear
extracts of A375 cells stimulated with rEGF incubated with a g-32P-labeled
oligonucleotide probe containing consensus binding sites for STAT5 in the
presence of antibodies against P-STAT5, P-STAT3, ERK, and P-ERK as
indicated. A supershift was only observed with P-STAT5 and, to a lesser
extent, with P-STAT3 antibodies.
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Figure 6. Treatment with siRNA-Stat5 reduced expression of target genes
Bcl-2 and cyclin D2. siRNA-Stat5 transfection of A375 cells showed a more
than 90% reduction of Stat5b transcript levels, whereas Stat5a gene
expression was unaffected. Real-time PCR also revealed a significant
reduction of Bcl-2 (Po0.005) and cyclin D2 transcripts (Po0.05).
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dominant-negative STAT5B fused to green fluorescent protein
(GFP). Analysis of DNA content in propidium iodide-stained
A375 cells transfected with wild-type and dominant-negative
human STAT5B (transfection efficiency: 22.275.7%; n¼ 3)
showed a 16.9-fold increase in the sub-G1-peak fraction
(indicative of apoptosis) for the dominant-negative mutant
(3.7272.04%) in relation to wild-type STAT5 (P¼0.04)
(Figure 9a). In the presence of rEGF, the difference was less
pronounced (4.3-fold 71.6) (Figure 9b), consistent with the
hypothesis that STAT5B activation inhibits apoptosis.
STAT5B-induced apoptosis was not seen in BLM cells in
accordance with the low EGFR levels and limited STAT5B
activation (Figure 9c and Figure 1d). Furthermore, dominant-
negative STAT5B inhibited the expression of bcl-2 in A375
cells (Figure 9c). Thus, inhibition of STAT5B signaling using
dominant-negative mutants led to G1 arrest and enhanced
cell death in rEGF-sensitive cells.
DISCUSSION
Since their discovery as key mediators of cytokine signaling,
considerable progress has been made in defining the
structure–function relationships of STATs (Darnell, 1997). In
addition to their central role in normal cell signaling, recent
studies have demonstrated that constitutively activated STAT
signaling directly contributes to oncogenesis and angiogen-
esis (Bowman et al., 2000; Niu et al., 2002b). Extensive
studies of primary tumors and tumor-derived cell lines
revealed that inappropriate activation of specific STATs
occurs with high frequency in a wide variety of human
cancers including leukemias (Lin et al., 2000), breast cancer
(Yamashita et al., 2003), prostate cancer (Li et al., 2004),
human non-small-cell carcinoma (Grandis et al., 2000; Xi
et al., 2003), and the lung cancer (Song et al., 2003).
In the present work, we have demonstrated an abundance
of stat5b transcripts and activation of STAT5 protein in
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Figure 7. siRNA-Stat5 transfection leads to decreased cell viability and
increased apoptosis. Reduced expression of Stat5b led to a 21.6% (NS) and
13.7% (NS) reduction in viability of BLM (a) and A375 (b) cells, respectively,
as evidenced by a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide assay. Blocking Stat5b expression led to a 1.5-fold apoptosis increase
in (c) BLM and a 2.58-fold increase in (d) A375 cells as assessed by the JC-1
FACS assay. As positive control, cisplatin (100 nM)-treated cells are shown
(*coefficient of variation: 109.39%).
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Figure 8. siRNA-Stat5 transfection leads to increased apoptosis. To confirm the JC-1 results suggesting apoptosis, annexinV staining was performed on
unstained, non-target and siRNA-Stat5b-treated (a) A375 and (b) BLM cells. As can be seen, upon treatment with siRNA-Stat5 a significant percentage of (a) A375
and (b) BLM cells became annexinV positive.
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approximately 71% of patients with cutaneous melanoma
metastases of different localizations. Activated STAT5 signal-
ing seems to play an important role in the malignant
transformation of melanocytes and growth of melanoma in
fish (Wellbrock et al., 1998).
The activation of STAT5 is ligand-, receptor-, and cell
type-specific and may also depend on activating stimuli
within the tumor microenvironment. In melanoma, STAT5
signaling may be induced by rEGF and is mediated by the
EGFR tyrosine kinase and by intracellular non-receptor
tyrosine kinases such as SRC and JAK1 (Coffer and Kruijer,
1995). Immunoprecipitation experiments with EGFR indi-
cated that SRC and not STAT5 or JAK1 directly interacts with
EGFR in melanoma cells. As SRC kinase and STAT5 were
associated in immunoprecipitates from A375 cell lysates only
after treatment with rEGF, this raises the possibility that upon
dissociation from the EGFR, SRC may directly phosphorylate
STAT5 when exogenous rEGF is present.
Furthermore, the inhibition of SRC abrogated the phos-
phorylation of STAT5. EGFR-mediated phosphorylation of
STAT5 may also occur through JAK1, whereas JAK2 seems
not to be generally involved in melanoma, in contrast to
prostate (Yamashita et al., 2003; Li et al., 2004) and breast
cancer (Canbay et al., 1997), where STAT5 is activated in
response to prolactin through JAK2. Therefore, the role of the
JAK family and SRC kinases depends on the particular
receptor–ligand interaction in a given cell type. In human
squamous cell carcinoma, it has been demonstrated that
STAT3 and STAT5 are activated through EGFR and SRC
family kinases (Chan et al., 2004), which corresponds to our
data of STAT5 activation through SRC in melanoma. In the
human squamous cell carcinoma xenograft model using
antisense oligonucleotides, it has been shown that STAT5B
and not STAT5A resulted in tumor growth inhibition and
abrogation of STAT5 target genes (Grandis et al., 2000). This
finding is in agreement with our results from transfection
assays with C-terminal-truncated dominant-negative
STATD5B constructs, which significantly enhanced cell death
and G1 cell arrest. These findings support a role for STAT5 in
cell cycle regulation and cell survival in melanoma. Recent
functional studies have also demonstrated that dominant-
negative STAT5 blocked cell proliferation and tissue invasion
and had a profound inhibitory effect on tumor progression
(Morcinek et al., 2002).
Furthermore, activation of STAT5 promoted cell cycle
progression in erythroid precursors and protection from
apoptosis through the upregulation of the STAT5 target gene
BCL-xL (Socolovsky et al., 1999; Krasilnikov et al., 2003).
Consistent with this finding, we investigated the expression of
antiapoptotic Bcl-2 and demonstrated strong expression in
clinical samples where STAT5 was active and in the
melanoma cell line A375 upon treatment with rEGF. siRNA
and transfection experiments with dominant-negative Stat5b
showed that induction of apoptosis in A375 cells correlated
with decreased expression of Bcl-2. This antiapoptotic effect
of dominant-negative Stat5b may act through the abrogation
of STAT5 target genes such as Bcl-2 (Morcinek et al., 2002;
Krasilnikov et al., 2003).
The participation of STAT signaling in tumor promotion
seems to be evolutionarily conserved, as constitutive activa-
tion of STAT5 by the EGFR-related Xmrk has been first
demonstrated in Xiphophorus melanoma cells, which re-
sulted in cell proliferation and prevention of apoptosis upon
stimulation with rEGF (Wellbrock et al., 1998; Morcinek
et al., 2002). Reduced expression of the product of the
marelle gene, a fly STAT homolog, has also been shown to
inhibit hematopoietic neoplasia (Hou et al., 1996).
The activation of STAT5 signaling in a variety of cancers
including melanoma (Wellbrock et al., 2005) point to the
importance of STAT5 signaling in cancer development. In
addition, our findings provide evidence that aberrant STAT5
signaling contributes to progression of melanoma by pre-
venting apoptosis and identifies SRC and STAT5 as potential
targets for therapeutic intervention.
MATERIALS AND METHODS
Cell culture
NHMs were cultured in phorbol 12-myristate 13-acetate-free
melanocyte medium (both obtained from PromoCell, Germany).
The human melanoma cell lines BLM, MV3, M13, A375 were
cultured in DMEM (Invitrogen-Gibco, Germany) under standard
conditions. Inhibitors of mitogen-activated protein kinase kinase -1/2
(U0126), of the EGFR (AG1478), JAK kinase (AG490), SRC kinase
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Figure 9. FACS analysis of DNA content of A375 and BLM cells after
transfection with different STAT5B vectors. Depicted are fold changes of
sub-G1 peaks at 72 hours relative to transfection with human STAT5B
wild-type (a) without or with rEGF treatment (n¼ 3). (b) BLM cells gated
for the sub-G1 phase without rEGF treatment (n¼ 3). The standard deviation
of three independent experiments is shown. Gray columns: all cells were
analyzed; white columns: only the transfected GFP-expressing cells were
analyzed; GFP: control transfection with GFP vector; hSTAT5BD726:
transfection with dominant-negative human STAT5B in which the 61
carboxy-terminal amino acids were deleted; and hSTAT5(WT): transfection
with human STAT5B wild-type. (d) Western blot analysis with Bcl-2 and
P-STAT5 antibodies with lysates of A375 transfected cells in presence of rEGF.
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(PP1, PP2) as well as cisplatin were obtained from Sigma-Aldrich,
Germany.
Tumor specimens
The melanoma metastases were from different biopsy sites (Table 1).
Biopsies were snap-frozen in liquid nitrogen and homogenized using
a dismembrator (Braun-Melsungen, Germany). One-half of the
powder was immediately transferred into TrizolTM reagent (Invitro-
gen, Germany) for total RNA isolation according to the manufac-
turer’s instruction and the other half transferred into ice-cold lysis
buffer containing 25 mM hydroxyethylpiperazine ethanesulfonic
acid, pH 7.9, 50 mM NaF, 1% Triton X-100, 5 mM EDTA, 100 mM
NaCl, and one tablet protease inhibitor cocktail per 10 ml buffer
(Roche, Germany) for Western blot analysis. Participants gave their
written informed consent. The study was conducted according to the
Declaration of Helsinki Principles.
Quantitative real-time PCR
The primers and the probe used for the detection of stat5b and 18S
were ordered as TaqMans gene expression assay (Applied
Biosystems Inc.). PCR was monitored in real time using the PRISM
7300 Sequence Detector (Applied Biosystems Inc., Foster City, CA).
All samples were amplified simultaneously in triplicate in one assay
run. Variation coefficients of CT values for triplicate reactions were
less than 1% for all gene products. The endogenous control showed
low interindividual coefficients of variation (8.5%).
Western blot analysis, immunoprecipitation,
immunohistochemistry, nuclear extraction, electrophoretic
mobility shift assay, and supershift assay
Total cell extracts were prepared in lysis buffer (see above) and
pretreated with ultrasound 10 pulses on ice. Immunostaining was
performed with using monoclonal antibodies against STAT5,
P-STAT5, Bcl-2 (each BD Biosciences Pharmingen, Becton Dickinson,
GmbH, Heidelberg, Germany), b-actin (Oncogene Research
Products, San Diego, CA), P-JAK1 (Y1022/1023), P-JAK2 (Y1007/1008)
(BioSource, Solingen, Germany) and P-SRC (Y215) (Sigma-Aldrich,
Taufkirchen, Germany). The EGFR (ErbB-1) antibody was obtained
from Cell Signaling, New England Biolabs, Germany. As a positive
control, the HaCaT epithelial cell line was used. For immuno-
precipitation samples in Western blot buffer were incubated with
EGFR or P-SRC antibodies overnight at 41C with constant rotation
followed by incubation with immobilized protein A/G (Pierce, Bonn,
Germany) for 2 hours. Immunohistochemistry of melanoma sections
was prepared as described (Mirmohammadsadegh et al., 2003).
Nuclear extraction and supershift assays were prepared as described
in Hassan et al. (2004). A375 cells were stimulated with rEGF
(100 ng/ml; BioSource) for 15 minutes. STAT5 double-stranded
oligonucleotides were from Santa Cruz Biotechnologies (Santa Cruz,
CA). The supershift assay was performed by preincubation of the
nuclear extracts with antibodies against P-STAT5, P-STAT3, phos-
phor-p44/42 mitogen-activated protein kinase (T202/Y204), and
p44/42 mitogen-activated protein kinase (each from Cell Signaling,
New England Biolabs, Germany).
RNA interference and apoptosis assay
siRNAs were provided by Dharmacon (Solingen, Germany). Cells
(2 105) were incubated with 100 nM siRNA transfection solution
without fetal calf serum and antibiotics for 4 hours. For real-time PCR
analysis, the incubation with siRNA lasted 24 hours and for FACS
analysis JC-1 apoptosis assay) 48 hours, respectively. Apoptosis was
measured by analyzing the change of the mitochondrial membrane
potential, using the membrane potential-sensitive dye JC-1. JC-1
(5mg/ml) in DMEM media containing 10% fetal calf serum were
added to the cells for 15 minutes in a 5% CO2 incubator at 371C.
Upon washes, cells were detached with trypsin, and centrifuged for
5 minutes at 500 g. Before suspension in 500ml phosphate-
buffered saline for flow cytometric analysis. AnnexinV staining
(Vybrant Apoptosis Assay kit no. 3, Invitrogen, Germany) was
assessed according to the manufacturer’s recommendations.
STAT5B vector construction
Human STAT5B wild-type cDNA was PCR-amplified from human
kidney cDNA (superscript III RT, Invitrogen). Primers for STAT5B
amplification were: 50-GCTAGCGATTGTAAACCATGGCTGTGT
GG-30 with an NheI site and 50-GAGCTCCGATTGTGCGTGCGG
GATCC-30 containing an SacI site instead of the stop codon. The PCR
product was ligated into pUC18 and sequenced (GATC company,
Konstanz, Germany). The internal SacI site was removed using
QuikChanges XL site-directed mutagenesis kit (Stratagene, CA)
using primers: 50-CGCGGCGTGTGGAGGAGCTGCTGGGCCGGC
CAATGGACA-30 and 50-TGTCCATTGGCCGGCCCAGCAGCTCCT
CCACACGCCGCG-30 conserving the amino-acid sequence. NheI/
SacI-STAT5B cDNA was ligated into NheI- and SacI-cut pEGFP-N1
(BD Biosciences, Pharmingen, Germany) resulting in pSTAT5B(WT)-
fus-GFP allowing the expression of a 119 kDa/787 amino acids
STAT5B-GFP fusion protein under the control of the cytomegalovirus
promotor. Construction of pSTAT5B(D726)fus-GFP was performed
accordingly using the primers 50-GCTAGCGATTGTAAACCATGG
CTGTGTGG-30 and 50-GAGCTCCGATTGTGCGTGCGGGATCC-30
allowing the expression of a 112 kDa protein.
Transfection assays
For transfections Polyfects (Qiagen, Germany) was used for A375
and JetPEIs (Q-BIOgene) for BLM cells, respectively. Transfection of 9 105
cells was performed according to the manufacturer’s recommendations
using 27mg of DNA and 162ml of Polyfects for A375 and 27mg of DNA
and 45 ml of JetPEIs for BLM cells, respectively.
FACS analysis
Cells were harvested and fixed in 3.7% paraformaldehyde (in
phosphate-buffered saline) for 1 hour. For permeabilization, 1 vol of
ice-cold 0.2% sodium citrate and 0.2% Triton X-100 (prepared in
phosphate-buffered saline) was added and incubated on ice for
2 minutes. After two phosphate-buffered saline washes, pellets were
resuspended in propidium iodide-staining solution (BD Biosciences
Pharmingen). DNA content was analyzed with a FACScalibur
(BD Biosciences Pharmingen) using Cell Quest.s
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